GSK PLC ADR (GSK): Price and Financial Metrics
GET POWR RATINGS... FREE!
GSK POWR Grades
- Value is the dimension where GSK ranks best; there it ranks ahead of 97.87% of US stocks.
- GSK's strongest trending metric is Quality; it's been moving up over the last 177 days.
- GSK's current lowest rank is in the Momentum metric (where it is better than 7.21% of US stocks).
GSK Stock Summary
- GSK has a market capitalization of $69,206,940,000 -- more than approximately 97% of US stocks.
- GSK PLC's stock had its IPO on July 9, 1986, making it an older stock than 93.08% of US equities in our set.
- With a price/earnings ratio of 3.84, GSK PLC P/E ratio is greater than that of about just 7.42% of stocks in our set with positive earnings.
- Stocks with similar financial metrics, market capitalization, and price volatility to GSK PLC are STLA, ATVI, NTES, EW, and PYPL.
- Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to www.gsk.com.
GSK Stock Price Chart Interactive Chart >
GSK Price/Volume Stats
| Current price | $35.58 | 52-week high | $46.97 |
| Prev. close | $35.27 | 52-week low | $28.47 |
| Day low | $35.39 | Volume | 2,799,900 |
| Day high | $35.74 | Avg. volume | 3,662,936 |
| 50-day MA | $34.97 | Dividend yield | 3.78% |
| 200-day MA | $35.30 | Market Cap | 76.70B |
GSK PLC ADR (GSK) Company Bio
GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck. (Source:Wikipedia)
Latest GSK News From Around the Web
Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, ProphylaxisA Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP), at no cost to patients. The ruling does not apply to preventive services, such as breast cancer screening, recommended before Obamacare was enacted in 2010. Eight individuals and two businesses brought the legal challenge. They argued that the free PrEP requirement requires business owners and con |
Why Is Scynexis (SCYX) Stock Up 69% Today?Scynexis (SCYX) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. |
Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSKThe Biden Administration told the U.S. Supreme Court on Wednesday that it should agree to hear a patent appeal over drug labels involving Teva Pharmaceuticals USA Inc and GlaxoSmithKline LLC that could have significant ramifications for the generic-drug industry. The U.S. Solicitor General said Teva's generic version of GSK's heart drug Coreg could not have violated GSK's patent rights because Teva omitted the infringing use of the drug from its labeling. Such "skinny labels" typically allow generic drugmakers to launch their products earlier while avoiding liability for infringing brand-name drugmakers' patents. |
GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio BucksGSK plc (NYSE: GSK) and Scynexis Inc (NASDAQ: SCYX) have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets). The FDA approved the antifungal for vulvovaginal candidiasis (VVC) and reduced the incidence of recurrent VVC (RVVC). This exclusive agreement gives GSK rights to commercialize Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase 3 trials for potentially treating invasive candidiasis (IC), which affects the blood or inter |
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention DrugViiV Healthcare and Medicines Patent Pool (MPP) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc (NASDAQ: VTRS) – through its subsidiary Mylan – to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP). Aurobindo Pharma and Viatris will manufacture in India. Cipla Limited will manufacture in India and plans to manufacture in South Africa too. ViiV Healthcare is majority owned by GSK Plc (NYSE: GSK), with Pfize |
GSK Price Returns
| 1-mo | 2.89% |
| 3-mo | 2.20% |
| 6-mo | 19.92% |
| 1-year | -15.67% |
| 3-year | 10.42% |
| 5-year | 16.73% |
| YTD | 2.20% |
| 2022 | -16.73% |
| 2021 | 26.64% |
| 2020 | -17.79% |
| 2019 | 29.12% |
| 2018 | 13.70% |
GSK Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching GSK
Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...